Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$55.24 USD

55.24
5,086,898

+0.92 (1.69%)

Updated Nov 4, 2024 01:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY

by Zacks Equity Research

A $75 million performance-based and program-based milestone payment has been triggered in favor of Evotec (EVO) under its strategic collaboration with Bristol Myers for molecular glue degraders.

Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results

by Zacks Equity Research

Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.

Ekta Bagri headshot

Bristol Myers (BMY) Gains 16% in a Month: Should You Buy or Wait?

by Ekta Bagri

Bristol Myers' (BMY) impressive second-quarter results propelled the stock in the past month. However, we advise investors not to be over-optimistic at this point and look before they leap.

Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues

by Zacks Equity Research

Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY.

Bristol Myers Squibb (BMY) Crossed Above the 200-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?

Ekta Bagri headshot

Biotech Stock Roundup: BMY, GSK, BIIB's Q2 Results, VTVT Down on Setback

by Ekta Bagri

Bristol Myers (BMY) and Biogen (BIIB) are in the spotlight following earnings results and regulatory updates, respectively.

BMY vs. VRTX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

BMY vs. VRTX: Which Stock Is the Better Value Option?

Pfizer (PFE) Beats on Q2 Earnings & Sales, Raises 2024 View

by Zacks Equity Research

Pfizer (PFE) beats second-quarter estimates for earnings and sales. It raises 2024 earnings as well as revenue expectations.

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Company News for Jul 29, 2024

by Zacks Equity Research

Companies in The News Are: NSC, CHTR, CL, BMY

PCE/Core PCE Inflation In Line With Estimates in June

by Zacks Equity Research

PCE/Core PCE Inflation In Line With Estimates in June.

Mark Vickery headshot

Pre-Markets Swell, PCE Behaves, Several Q2 Beats

by Mark Vickery

Pre-market futures are jumping this morning, though this may have to do with favorable market conditions after the sell-off mid-week.

Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View

by Zacks Equity Research

Bristol-Myers (BMY) posts impressive second-quarter results, with both earnings and sales beating their respective estimates. The company also raises its annual earnings guidance.

Bristol Myers (BMY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 26.22% and 5.93%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

DECK, SKX Higher After Earnings; PCE On Tap Friday

by Mark Vickery

The maker of Hoka footwear, UGG boots and more, posted a giant beat on its fiscal Q1 bottom line.

Sweta Killa headshot

What Lies in Store for Healthcare ETFs in Q2 Earnings?

by Sweta Killa

The healthcare sector has gained momentum lately on market rotation, with investors rushing to buy beaten-down stocks while shunning the hot technology sector.

Kinjel Shah headshot

Pfizer (PFE) Q2 Earnings Coming Up: What Should Investors Do?

by Kinjel Shah

Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen

The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences

by Zacks Equity Research

Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences are part of the Zacks Top Analyst Blog.

Ekta Bagri headshot

Should You Buy, Sell or Hold Bristol Myers (BMY) Before Q2 Earnings?

by Ekta Bagri

Bristol Myers (BMY) has an uphill task at hand. Given the current challenges, we would advise investors to avoid BMY ahead of the second-quarter results.

Ahan Chakraborty headshot

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

by Ahan Chakraborty

Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q2 Release

by Zacks Equity Research

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EMA Begins Review of Bristol Myers' (BMY) Opdivo Plus Yervoy for HCC

by Zacks Equity Research

Bristol Myers' (BMY) application seeking approval for Opdivo, in combination with Yervoy, for the indication of advanced hepatocellular carcinoma gets validation in the EU.

Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for Investors

by Zacks Equity Research

The latest trading day saw Bristol Myers Squibb (BMY) settling at $42.39, representing a -1.76% change from its previous close.